STTK - Shattuck Labs Inc logo

Shattuck Labs Inc

STTK

Shattuck Labs develops antibody therapies for inflammatory and immune-mediated diseases, focusing on treatments like SL-325 for inflammatory bowel disease and other conditions, with several preclinical and clinical programs targeting various pathways.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$335today

Score Overview

1 Year
Score
Net Growth-7.70%
Net TrendShrank
Net Income Consistency—
Rev Growth0.00%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.0
Net Growth-16.89%
Net Trend60%
Net Income Consistency—
Rev Growth-96.67%
Rev Trend40%
Revenue Consistency—
All Time
Score
Net Growth-48.35%
Net Trend50%
Net Income Consistency
Rev Growth-89.93%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Shattuck Labs Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. STTK does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 6.82—
1 Year2025-09-30
$ 2.39185.36%
5 Years2021-09-30
$ 20.38-66.54%
All Time2020-10-09
$ 19.35-64.75%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1M-$ 52M$ 63M
2025$ 1M-$ 48M$ 78M
2024$ 5M-$ 75M$ 72M
2023$ 1M-$ 87M$ 130M
2022$ 652K-$ 100M$ 161M
2021$ 30M-$ 44M$ 268M
IPO2020$ 9M-$ 35M$ 335M
STTK - Shattuck Labs Inc logo

Shattuck Labs Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 9M to $ 1M and net income went from -$ 35M to -$ 48M. Revenue increased in 2 of those 5 years; net income in 3.

Shattuck Labs Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Explore STTK with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies